ArticlePloS one2007
Tagging single nucleotide polymorphisms in the BRIP1 gene and susceptibility to breast and ovarian cancer.
Article in PloS one, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Clinical and Prognostic Relevance of BRIP1 Expression in Colorectal Cancer: Evidence from TCGA and Korean Cohorts.Medicina (Kaunas, Lithuania) · 2025Article
- Male Breast Cancer With Dual BRCA2 and BRIP1 Deleterious Gene Mutations.Ochsner journal · 2024Article
- Molecular Genetic Characteristics ofGenes · 2023Article
- A functionally impaired missense variant identified in French Canadian families implicates FANCI as a candidate ovarian cancer-predisposing gene.Genome medicine · 2021Article
- The repair geneOncology reviews · 2021Article
- CSMD3 is Associated with Tumor Mutation Burden and Immune Infiltration in Ovarian Cancer Patients.International journal of general medicine · 2021Article
- Comparison of Patient Susceptibility Genes Across Breast Cancer: Implications for Prognosis and Therapeutic Outcomes.Pharmacogenomics and personalized medicine · 2020Review
- Andrographolide induces DNA damage in prostate cancer cells.Oncotarget · 2019Article
- Article
- Association of Single-Nucleotide Polymorphisms in Monoubiquitinated FANCD2-DNA Damage Repair Pathway Genes With Breast Cancer in the Chinese Population.Technology in cancer research & treatment · 2018Article
- Genetic association between HER2 and ESR2 polymorphisms and ovarian cancer: a meta-analysis.OncoTargets and therapy · 2018Article
- BRIP1 inhibits the tumorigenic properties of cervical cancer by regulating RhoA GTPase activity.Oncology letters · 2016Article
- An unsupervised learning approach to find ovarian cancer genes through integration of biological data.BMC genomics · 2015Article
- Correlation of the BACH1 Pro919Ser polymorphism with breast cancer risk: A literature-based meta-analysis and meta-regression analysis.Experimental and therapeutic medicine · 2013Article
- Role of DNA repair and cell cycle control genes in ovarian cancer susceptibility.Molecular biology reports · 2013Article
- Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer.International journal of cancer · 2011Article
- Hereditary breast cancer and the BRCA1-associated FANCJ/BACH1/BRIP1.Future oncology (London, England) · 2011Review
- Association between DNA damage response and repair genes and risk of invasive serous ovarian cancer.PloS one · 2010Article
- Absence of truncating BRIP1 mutations in chromosome 17q-linked hereditary prostate cancer families.British journal of cancer · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
backgroundBRIP1 interacts with BRCA1 and functions in regulating DNA double strand break repair pathways. Germline BRIP1 mutations are associated with breast cancer and Fanconi anemia. Thus, common variants in the BRIP1 are candidates for breast and ovarian cancer susceptibility.
methodsWe used a SNP tagging approach to evaluate the association between common variants (minor allele frequency>or=0.05) in BRIP1 and the risks of breast cancer and invasive ovarian cancer. 12 tagging SNPs (tSNPs) in the gene were identified and genotyped in up to 2,270 breast cancer cases and 2,280 controls from the UK and up to 1,513 invasive ovarian cancer cases and 2,515 controls from the UK, Denmark and USA. Genotype frequencies in cases and controls were compared using logistic regression.
resultsTwo tSNPs showed a marginal significant association with ovarian cancer: Carriers of the minor allele of rs2191249 were at reduced risk compared with the common homozygotes (Odds Ratio (OR) = 0.90 (95% CI, 0.82-1.0), P-trend = 0.045) and the minor allele of rs4988344 was associated with increased risk (OR = 1.15 (95%CI, 1.02-1.30), P-trend = 0.02). When the analyses were restricted to serous ovarian cancers, these effects became slightly stronger. These results were not significant at the 5% level after adjusting for multiple testing. None of the tSNPs was associated with breast cancer.
conclusionsIt is unlikely that common variants in BRIP1 contribute significantly to breast cancer susceptibility. The possible association of rs2191249 and rs4988344 with ovarian cancer risks warrant confirmation in independent case-control studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.